A randomized, double-blind, placebo-controlled Phase II Efficacy and Safety Study of the PDE10A inhibitor PF-02545920 in Huntington Disease (AMARYLLIS)
Objective: To assess efficacy on motor function, safety and tolerability of the phosphodiesterase-10A inhibitor PF-02545920 in Huntington disease (HD). Conclusion: PF-02545920 was generally safe and…Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor
Objective: To investigate the effects of selective phosphodiestrase (PDE) inhibitors in Nimodipine induced neuro degeneration (animal models of Huntington’s disease) in rats. Background: Nimodipine is…Decision making in Huntington’s disease
Objective: To investigate perceptual decision making and reflexion impulsivity in preclinical and manifest patients with Huntington’s disease (HD). Background: Huntington’s disease (HD) is an autosomal…Clinical and genetic data of Huntington disease in Uzbekistan patient
Objective: Huntington's disease (HD) occurs worldwide with prevalence varying from 0.1 to 10/100,000 depending of the ethnic origin. Since no data is available in the…Interrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score certification
Objective: The aim of this study was to investigate the interrater reliability of the Unified Huntington’s Disease Rating Scale-Total Motor Score (UHDRS-TMS) and of its…Speech in Huntington’s Disease
Objective: To review existing literature on speech function in Huntington’s disease (HD) across the disease spectrum. Background: Impairment in speech production affects the majority of…Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease
Objective: To assess cerebrospinal fluid (CSF) mutant Huntingtin (mHTT), and CSF and plasma neurofilament light (NfL) in Huntington’s disease (HD). Background: HD is a progressive…Neuronal correlates of oculomotor alterations in Huntington’s disease. A 18-FDG PET study
Objective: To explore the neuroanatomical correlates of the oculomotor abnormalities in Huntington's disease (HD) through a 18-FDG PET study Background: Alterations of the oculomotor function…Treating Huntington’s Disease using a holistic approach
Objective: Huntington’s disease (HD) is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical…Cognitive Reserve and Physical Activity Modulate Functional Brain Re-organisation in Premanifest Huntington’s Disease: Preliminary Evidence
Objective: In this study, for the first time we examined the relationship between cognitive reserve, sleep quality and current level of physical exercise and functional…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.